Hepion Pharmaceuticals, Inc. 8-KCurrent Reports (8-K / ad hoc)

Market for Equity / Stockholders

Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On July 1, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of Danina Fisher and Gary S. Stetz, II as directors of the Company, effective immediately. There are no arrangements or understandings between Ms. Fisher and Mr. Stetz and any other person pursuant to which such person was selected as a director of the Company, and there is no family relationship between any of Ms. Fisher and Mr. Stetz, except that Mr. Stetz is Gary Stetz’s son. Field: Page; Sequence: 2; Options: NewSection; Value: 2 - Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence - Field: /Page SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 2, 2026 Hepion Pharmaceuticals, Inc. By: /s/ Gary Stetz Gary Stetz Interim Chief Executive Officer Field: Page; Sequence: 3; Options: Last - Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence - Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6PbQr/sAuHTrEKTJEvC0uk+LWjLT+PZJvad0QQyAk53w5QsQip5VpkOG0KAs4YNs12iOUWCOjPWNwZOtNCmGWeDHOs7a+X39gRoHBwMxGUx3uvfNuHFYpyPlYJmM1A6lSNYH9VkRfPSNbmwqtN7oBbSvYM3Vs0Gt+DR8O+kmW2lefdER2hmwKyUgO8huUTBTs6K4fxFcHRZGJKO4rEjnTrQuu5dOj/ZKwbLANcW6g/x19AMuwSlw=